An oral suspension formulation of edaravone (MT-1186) is safe and well-tolerated in adults with amyotrophic lateral sclerosis (ALS), according to interim, six-month data from a Phase 3 clinical trial. In addition, exploratory efficacy results suggest that edaravone’s experimental oral formulation may slow patients’ functional decline to a similar level…
Before his recent death, motor neuron disease (MND) patient Anthony Walsh had the opportunity to try a prototype Toyota Human Support Robot (HSR), providing a glimpse into the kind of technology that could be used to help people with amyotrophic lateral sclerosis and other MNDs with everyday tasks. Walsh, who was…
My husband Todd’s lung strength is weak from ALS. He’s gotten sick a few times in the last several years, and each time we wondered if he would pull through. It was scary, and it has caused us to calculate the risk of going out in public or receiving…
While it’s long been believed that the death of motor neurons in the spinal cord is the main cause of amyotrophic lateral sclerosis (ALS), new research suggests that degeneration of motor neurons in the brain takes place independently and may also contribute to the disease. The study’s work in…
“In-A-Gadda-Da-Vida” Last week, my pastor humorously suggested I should challenge folks to put forth songs or lyrics they believed I wouldn’t be able to kick-start a column with. He further suggested the above mentioned track by Iron Butterfly would be such a stumper. I respectfully submit that he…
A Phase 2 trial of ZZ Biotech’s investigational therapy 3K3A-APC in people with amyotrophic lateral sclerosis (ALS) has started dosing patients at its single site in Australia, the company announced in a press release. The open-label trial (NCT05039268), underway at the Macquarie University in Sydney, aims to evaluate…
My ALS symptoms showed up in my feet and legs in 2010. Normally strong and coordinated from years of gymnastics and fitness classes, my lower limbs became weak and unreliable. That’s when my neurologist recommended I begin using a walker. To be precise, she meant I use a…
CNM-Au8, an investigational disease-modifying therapy for people with early amyotrophic lateral sclerosis (ALS), showed consistent clinical benefits in patients with both limb and bulbar onset disease, according to new analyses of RESCUE-ALS Phase 2 clinical trial data. In particular, the treatment significantly extended the time to disease progression —…
When Leah Stavenhagen was 27, she was living in Paris and traveling through Europe. But an amyotrophic lateral sclerosis (ALS) diagnosis forced her to give up her job as a consultant with Ernst & Young and dashed her dreams of continuing to work abroad. At the time, she seemed…
Repeat injections of mesenchymal stem cells (MSCs) into the spinal canal were safe and well tolerated in patients with amyotrophic lateral sclerosis (ALS), and showed potential to significantly slow the rate of disease progression, a small Phase 2 clinical trial found. “Larger studies are warranted to confirm our observations…
